Tyra Bioscience (TYRA – Research Report) received a Buy rating and a $12.00 price target from H.C. Wainwright analyst Mitchell Kapoor today. The company’s shares closed last Wednesday at $6.27, close to its 52-week low of $4.93.
According to TipRanks.com, Kapoor is ranked #6386 out of 7895 analysts.
Currently, the analyst consensus on Tyra Bioscience is a Moderate Buy with an average price target of $12.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Tyra Bioscience’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.93 million. In comparison, last year the company had a GAAP net loss of $4.21 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tyra Biosciences Inc is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
Read More on TYRA:
- H.C. Wainwright Reaffirms Their Buy Rating on Vaccitech Plc (VACC)
- H.C. Wainwright Sticks to Their Buy Rating for Vertex Energy (VTNR)
- J.P. Morgan Sticks to Their Buy Rating for Nike (NKE)
- Analysts Are Bullish on These Healthcare Stocks: Aslan Pharmaceuticals (ASLN), Precision BioSciences (DTIL)
- Analysts’ Top Materials Picks: Calumet Specialty Products (CLMT), Western Copper (WRN)
